Effect of docetaxel chemotherapy for peritoneal perfusion in elderly patients with gastric and malignant ascites
ZHU Xiaopeng
TANG Ze
YANG Lihua
Abstract:Objective To compare the effect of docetaxel peritoneal perfusion and Cisplatin infusion chemotherapy in elderly with gastric cancer and malignant ascites.Methods Eighty cases of elderly patients with gastric cancer and malignant ascites with KPS score ranked from 50 to 70 points were randomly divided into research group ( docetaxel abdominal hot perfu-sion chemotherapy) with 40 cases and control group ( heat cisplatin intraperitoneal perfusion chemotherapy) with 40 cases, to observe the curative effect, KPS score, tumor markers and adverse reactions of the two groups of patients.Results The total effective rate of research group was 70.0%(28/40), which was significantly higher than control group’s 47.5%(19/40), (χ2 =4.178, P <0.05;disease control rate was 87.5% (35/40), which was higher than control group’ s 67.5% (27/40),(χ2 =4.588, P <0.05).Before treatment, research group and control group’ s KPS scores were (56.50 ±5.80) points and (56.25 ±6.28) points, KPS score after treatment was (66.50 ±9.49) points and (68.25 ±8.44) points, which were better than before treatment in both of the two groups ( t =-6.817, t =-5.942, P <0.05); compared with before treatment, after treatment’ s CEA, CA125, CA199 decreased significantly (research group:t =6.593, t =2.189, t =1.606, P <0.05;control group:t =6.125, t =2.099, t =1.897, P <0.05), but no significant differences were found be-tween before and after treatment in both of the two groups (before treatment:t =0.213, t =-0.973, t =0.103, P >0.05;after treatment:t =-0.422, t =-0.945, t =0.872, P >0.05);Research group’s gastrointestinal reactions was 17.5%(7/40),which was lower than control group’s 37.5%(15/40)with a statistically significant difference(χ2 =4.013, P <0.05).Conclusion Docetaxel chemotherapy for treated peritoneal perfusion in elderly patients with gastric and malignant asci-tes revealed good effect, it can improve the quality of life and reduce the tumor markers level, and release the adverse reactions.
Keywords:DocetaxelIntraperitoneal hyperthermic perfusion chemotherapyGastric cancerMalignant ascites
Publication Date:2015-01-01
Online Publishing Date:2025-08-15(First online date of this platform, not the publication date of the document)
Pages:4( 487-490 )
